Board of Directors
Wayne B. Weisman
Chairman of the Board
Wayne B. Weisman has been a director of the company and the chairman of our board since 2008. Since 2007, Mr. Weisman has been a director of the corporate general partner of the common general partner of SCP Vitalife, which beneficially owns 33.6% of our outstanding stock as of April 1, 2016. He has also served as a managing member of SCP Vitalife Management Company, LLC, which by contract provides certain management services to the common general partner of SCP Vitalife.
Mr. Weisman has also led the activities of SCP Private Equity Partners II, L.P., a venture capital fund of which he and Mr. Churchill are principals in the life sciences area. His activities include investments in the United States and Israel. He has also led several other technology investments for SCP Private Equity Partners II, L.P. He has been a member of the investment committee of the Vitalife Life Sciences funds since their inception in 2002 and has worked closely with these funds since then.
Mr. Weisman has been a member of the board of directors of CIP Capital L.P., a small business investment company licensed by the U.S. Small Business Administration since its inception in 1991. From 1992 to 1994, Mr. Weisman was executive vice president and member of the board of directors of a public drug delivery technology company. In addition, he also operated a management and financial advisory firm focusing on the reorganization and turnaround of troubled companies and began his career practicing reorganization law at a large Philadelphia law firm.
Mr. Weisman possesses extensive experience in venture capital investing, particularly in the life sciences area. He serves on the board of ReWalk Robotics Ltd. and on a number of private company boards including the boards of DIR Technologies, Endospan Ltd., Ivenix, LLC, and Echo360, Inc. Mr. Weisman is the chairman of the boards of trustees of Young Scholars School, Young Scholars Frederick Douglass, and Young Scholars Kenderton. He is also an advisory board member of the Philadelphia-Israel Chamber of Commerce and Mid-Atlantic Diamond Ventures, the venture forum of Temple University. Mr. Weisman holds a B.A. from the University of Pennsylvania, and a J.D. from the University of Michigan Law School.
As a long time director of our company, Mr. Weisman’s extensive knowledge of our business and history, experience as a board member of multiple publicly traded and privately held companies, and expertise in developing, financing, and providing strong executive leadership to numerous growing life science companies contributed to our board’s conclusion that he should serve as a director of our company.
William L. Ashton
William L. Ashton has been a director of the company since 2009. Since the beginning of 2013, Mr. Ashton has been a principal at Harrison Consulting Group, Inc., a privately-held biopharmaceutical consulting firm. From August 2009 to June 2013, he was the senior vice president of external affairs reporting to the president and an assistant professor at the University of the Sciences in Philadelphia, Pennsylvania. From August 2005 to August 2009, Mr. Ashton was the founding dean of the Mayes College of Healthcare Business and Policy.
Mr. Ashton has 29 years of experience in the biopharmaceutical industry. From 1989 to 2005, he held a number of positions at Amgen Inc., a biotechnology company, including vice president of U.S. sales and vice president of commercial and government affairs. Mr. Ashton currently serves on the boards of directors of Galena Biopharma, Inc. and Sucampo Pharmaceuticals, Inc. He is also a member of the board of directors of the National Osteoporosis Foundation and Friends of the National Library of Medicine at the National Institutes of Health. Mr. Ashton holds a B.S. in education, from the California University of Pennsylvania and an M.A. in education from the University of Pittsburgh.
Mr. Ashton’s extensive experience with pharmaceutical and biological products’ commercialization and reimbursement issues, his past advisory role during the early years of Auxilium, as well as his experience as a board member of privately held companies, and his scientific expertise contributed to our board’s conclusion that he should serve as a director of our company.
Michael Berelowitz, M.D.
Michael Berelowitz was elected to our board in March 2014 upon the consummation of our IPO. Since 2011, Dr. Berelowitz has served as a biopharmaceutical consultant. From 2009 to 2011, he was senior vice president and head of clinical development and medical affairs in the specialty care business unit at Pfizer, Inc., a pharmaceutical company. From 1996 to 2009, he held various other roles at Pfizer, Inc., beginning as a medical director in the diabetes clinical research team and then assuming positions of increasing responsibility.
Prior to that, Dr. Berelowitz spent a number of years in academia. He also serves on the board of directors of Oramed Pharmaceuticals Inc. Among his public activities, Dr. Berelowitz has served on the board of directors of the American Diabetes Association and the Clinical Initiatives Committee of the Endocrine Society and has chaired the Task Force on Research of the New York State Council on Diabetes. He has also served on several editorial boards, including the Journal of Clinical Endocrinology and Metabolism and Endocrinology, Reviews in Endocrine and Metabolic Disorders, and Clinical Diabetes.
Dr. Berelowitz has authored and co-authored more than 100 peer-reviewed journal articles and book chapters in the areas of pituitary growth hormone regulation, diabetes, and metabolic disorders. He holds adjunct appointments as a professor of medicine in the divisions of endocrinology and metabolism at SUNY Stony Brook and Mt. Sinai School of Medicine in New York. Dr. Berelowitz’s years of experience in management roles in the pharmaceuticals industry, as well as his vast skill and expertise in the fields of endocrinology and diabetes, contributed to our Board’s conclusion that he should serve as a director of our company.
Winston J. Churchill
Winston J. Churchill has been a director of the company since 2008. Since 2007, Mr. Churchill has been a director of the corporate general partner of the common general partner of SCP Vitalife, which beneficially owns 33.6% of our outstanding stock as of April 1, 2016. He has also served as a managing member of SCP Vitalife Management Company, LLC, which by contract provides certain management services to the common general partner of SCP Vitalife.
Mr. Churchill has also served since 1993 as the president of CIP Capital Management, Inc., the general partner of CIP Capital, L.P., an SBA-licensed private equity fund. Prior to that, he was a managing partner of Bradford Associates, which managed private equity funds on behalf of Bessemer Securities Corporation and Bessemer Trust Company.
From 1967 to 1983, Mr. Churchill practiced law at the Philadelphia firm of Saul Ewing, LLP, where he served as chairman of the banking and financial institutions department, chairman of the finance committee, and was a member of the executive committee. Mr. Churchill is a director of Griffin Land & Nurseries, Inc., Innovative Solutions and Support, Inc., Amkor Technology, Inc., and various SCP Vitalife portfolio companies. In addition, he serves as a director on the boards of a number of charities and as a trustee of educational institutions including the Gesu School and Scholar Academies and is a trustee fellow of Fordham University.
From 1989 to 1993, Mr. Churchill served as chairman of the finance committee of the Pennsylvania Public School Employees’ Retirement System. He was awarded a B.S. in physics, summa cum laude, from Fordham University, followed by an M.A. in economics from Oxford University, where he studied as a Rhodes Scholar and a J.D. from Yale Law School.
As a longtime director of our company, Mr. Churchill’s extensive knowledge of our business and history, experience as a board member of multiple publicly traded and privately held companies, and expertise in developing, financing, and providing strong executive leadership to numerous growing life science companies contributed to our Board’s conclusion that he should serve as a director of our company.
J. David Enloe, Jr.
President and Chief Executive Officer
J. David Enloe brings over two decades of executive leadership experience in biotechnology, clinical drug development, and GMP manufacturing. Most recently, he served as president and chief executive officer of Ajinomoto Bio-Pharma Services, a global, fully integrated CDMO.
Prior to joining Ajinomoto, Mr. Enloe served as head of Lonza’s Viral Therapeutics business unit, which was the result of Lonza’s acquisition of Vivante GMP Solutions, a gene therapy CDMO that he founded in June 2009 and where he served as president and CEO until its sale to Lonza AG. Under Mr. Enloe’s leadership, the business experienced rapid expansion, with revenues increasing 500% over a three-year period.
Preceding Vivante, Mr. Enloe spent 14 years with the biotech company, Introgen Therapeutics, joining as its first employee in 1995 and serving as senior vice president and COO before being named president and CEO. Mr. Enloe served an integral role in taking the company through a successful IPO in 2020, as well as several other significant financial transactions. In addition, he oversaw multiple large corporate and academic collaborations, as well as the filing of license applications with both the FDA and European regulatory authorities for Introgen’s lead product.
Mr. Enloe received a Bachelor of Business Administration, Accounting, from the University of Texas at Austin. He is a Certified Public Accountant and started his career in public accounting with Arthur Andersen & Co.
Gerri Henwood has served on the board of directors of Recro Pharma since founding the company in 2008. Since November of 2019, she has served as president, chief executive officer, and director of Baudax Bio (BXRX). From 2008 to December 2020, Ms. Henwood was the president and chief executive officer of Recro Pharma (REPH). From 2006 to 2013, Ms. Henwood served as the president of Malvern Consulting Group, Inc., or MCG, a pharmaceutical incubator and consulting firm. Before founding MCG, she was the president and chief executive officer of Auxilium Pharmaceuticals, Inc. (formerly AUXL), or Auxilium, a biopharmaceutical company she founded in late 1999. From 1985 to 1999, Ms. Henwood was the founder and chief executive officer of IBAH, Inc., or IBAH, a contract research organization listed on NASDAQ. She began her career with Smith Kline & French, now part of GlaxoSmithKline plc. She rose through the ranks to be a brand manager, then the head of regulatory and medical affairs for the U.S. business, and then to the position of group director—marketing in the International Pharmaceutical Division.
Ms. Henwood previously served on the board of directors of Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, from 2015 until its acquisition by La Jolla Pharmaceutical Company in June 2020. Before that, she served on the board of directors of Alkermes, Inc. and its successor company, Alkermes, plc, a global biopharmaceutical company, from 2003 until March 2015, and on the board of directors of MAP Pharmaceuticals, Inc., a biopharmaceutical company, from 2004 until its acquisition by Allergan, Inc. in March 2013. Ms. Henwood also served on the compensation committee of the board of directors of Tetraphase Pharmaceuticals, Inc.
Ms. Henwood holds a B.S. in biology from Neumann University.
In his current roles as senior vice president of finance and chief financial officer of Impax Laboratories, Mr. Reasons’ responsibilities span accounting, financial planning and analysis, business development and investor relations, and corporate communications. Prior to joining Impax in 2012, Mr. Reasons held positions of increasing responsibility at Cephalon, Inc., where he successfully navigated acquisition by Teva Pharmaceutical Industries Ltd. for eight billion dollars. He previously served in a number of financial leadership roles at E.I. du Pont de Nemours and Company and PricewaterhouseCoopers LLP, ranging from corporate accounting, external reporting and audit, and business advisory services.
Mr. Reasons earned a bachelor’s degree in accounting from Pennsylvania State University and an MBA from Widener University. He is a certified public accountant.
Jim Miller is an advisor on manufacturing strategy and a pre-eminent authority on the biopharmaceutical contract manufacturing and development industry. Mr. Miller is the founder and former President of PharmSource, the industry’s principal source of market intelligence. PharmSource was sold in 2016 to Global Data, a London-based, publicly traded provider of market intelligence services.
Mr. Miller has advised most major CMOs on business strategy, major capital investment decisions, and acquisitions. He has served on due diligence teams for high-profile acquisitions made by private equity firms. In 2017 and 2019, he was named one of the 100 most influential people in the pharmaceutical industry by Medicine Maker magazine.
Mr. Miller was a corporate strategy consultant at the Boston Consulting Group and an economist at The World Bank. He holds an MBA from the Stanford University Graduate School of Business.
Laura L. Parks
Laura Parks is a transformational business leader with a record of developing high-performance, market-focused teams. She led strategic commercial and operational initiatives as part of the executive leadership team at Patheon, a global biopharma contract development and manufacturing organization until its acquisition by Thermo Fisher Scientific.
Before that role, Dr. Parks served as president of DSM Pharmaceuticals, the $250M steriles and oral solid dosage finished dose contract manufacturing organization of DSM (merged with Patheon Mar 2014). She was promoted to that position after successfully leading the business unit’s marketing and sales team and functional excellence globally for DSM’s BioPharma business.
In the food ingredient industry, Dr. Parks was regional vice president, North America for Solae, a division of DuPont, where she led a $120 million business unit. She was vice president of sales for Solae for two years.
Dr. Parks earned a Ph.D. in Food Science from the University of Georgia and a Bachelor of Science from The Ohio State University. Dr. Parks currently serves on the Advisory Board of Lindy BioSciences in Durham, NC, and volunteers with Every Child Reading and a service dog training organization in Denver and the central Colorado mountains.